Study On FA2H As A Herapeutic Target And Prognostic Factor For Breast Cancer

Objective:To investigate the differential expression of FA2H in different subtypes of breast cancer,its association with pathological features,prognosis,and drug sensitivity.The results of the study were used to evaluate FA2H as a therapeutic target.And the feasibility of the prognostic factor.Methods:The expression of FA2H in different cancers was evaluated by Oncomine database,and the expression data in breast cancer was extracted.The expression and characteristics of FA2H in breast cancer cell lines were analyzed by GOBO database.The tissue samples of 101 breast cancer patients who underwent surgery from the First Affiliated Hospital of Soochow University from 2016 to 2018 were collected for FA2H expression and correlated with the patient's basic information characteristics and disease information characteristics.The effect of FA2H expression in different subtypes of breast cancer on prognosis was analyzed by Kaplan-Meier plotter.The FA2H cell line up to the table was searched in the GOBO database,and the cell line was subjected to gene silencing to study the relationship between the expression of FA2H and the sensitivity of the therapeutic drug in the cell line.Results:The data were retrieved from the Oncomine database and the expression of FA2H was overexpressed in human breast cancer.Statistical data were found in the GOBO database.The expression of FA2H mRNA was highest in ER positive cell lines,and human epidermal growth was observed.The HER2 positive subtype followed,and the TN subtype was the lowest.In the 101 patient data collected,it was found that the difference in molecular typing,ER status,Ki67 expression,lymph node metastasis,and tumor stage,FA2H expression was different.The age,menopausal status,and PR status are not.Kaplan-Meier plotter analysis showed that the RFS prolongation in the FA2H low expression group was prolonged in 3951 patients,and the OS2 prolongation in the FA2H low expression group was prolonged in 1402 patients.The difference was statistically significant.The data were classified and found to be ER positive,histopathological grades were G2 and G3,HER2.The positive expression of RFS in the low expression group of FA2H with positive and negative lymph node metastasis was statistically significant,while the difference of RFS between the high and low expression groups with negative ER negative and lymph node metastasis was not statistically significant.All patients with Luminal A subtype in molecular typing and those receiving medical treatment or chemotherapy showed an increase in RFS prolongation in the low expression group of FA2H,and the difference was statistically significant,while in Luminal B,HER2 amplification,and Basal-like subtypes.The difference was not statistically significant.The high expression of FA2H in the T47D cell line was found in the GOBO database,and down-regulation of FA2H could significantly increase the sensitivity of the cells to drugs and reduce the expression of drug resistance genes.Conclusion:The results suggest that FA2H is highly expressed in breast cancer,and its expression is different in different subtypes,and is associated with prognosis.In some subtypes,the low expression of FAS in the FA2H group is prolonged,so FA2H can be used as a breast cancer.A new prognostic factor,while also down-regulating the expression of FA2H,can also increase the sensitivity of breast cancer cells to drugs,suggesting a certain clinical application value after certain interventions on FA2H.